• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-550-095 Revised 02-May-06
Tamoxifen . citrate
Add to Clipboard
SYNONYMS (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethanamine . citrate
PRODUCT LINE Cancer
PRODUCT CATEGORY Antitumor Agents (Hormone-related)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-095-G001   1 g 85.00 USD Add To Cart
Product Specification
FORMULA: C26H29NO . C6H8O7
MW: 371.5 . 192.1
CAS NUMBER: 54965-24-1
MERCK INDEX: 14: 9048
RTECS: KH2387000
PURITY: ≥99%
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in methanol; very slightly soluble in water or acetone.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: TOXIC. MAY BE TERATOGENIC. MAY BE CARCINOGENIC.

Product Description
Antiestrogen. Selective protein kinase C (PKC) inhibitor. Induces apoptosis.
Product Specific Literature References
Inhibition of protein kinase C by tamoxifen: C.A. O'Brian, et al.; Cancer Res. 45, 2462 (1985) Abstract
Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells: M. Issandou, et al.; Cancer Res. 50, 5845 (1990) Abstract
Signalling targets for anticancer drug development: G. Powis; TIPS 12, 188 (1991), (Review) Abstract
Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines: W.T. Couldwell, et al.; FEBS Lett. 345, 43 (1994) Abstract
Tamoxifen: teaching an old drug new tricks?: D.J. Grainge & J.C. Metcalfe; Nat. Med. 2, 381 (1996), (Review) Abstract
Genomic effects of tamoxifen: J.A. Kellen; Anticancer Res. 16, 3537 (1996) Abstract
Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal: R.E. Favoni & A. de Cupis; TIPS 19, 406 (1998), (Review) Abstract
Recent advances in understanding the molecular mechanisms of tamoxifen action: Z.Y. Friedman; Cancer Invest. 16, 391 (1998) Abstract
Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells: M. Maccarrone, et al.; FEBS Lett. 434, 421 (1998) Abstract
Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review): S. Toma, et al.; Int. J. Oncol. 15, 321 (1999) Abstract
Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes: D.A. Cameron, et al.; Eur. J. Cancer. 36, 845 (2000) Abstract
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells: S. Mandlekar, et al.; Cancer Res. 60, 5995 (2000) Abstract; Full Text
Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines: S. Mandlekar, et al.; Cancer Res. 60, 6601 (2000) Abstract; Full Text
Update on clinical role of tamoxifen: J.R. Benson and V. Pitsinis; Curr. Opin. Obstet. Gynecol. 15, 13 (2003) Abstract
Tamoxifen for prevention of breast cancer: R.J. Cersosimo; Ann. Pharmacother. 37, 268 (2003) Abstract
Tamoxifen: a most unlikely pioneering medicine: V.C. Jordan; Nat. Rev. Drug Discov. 2, 205 (2003) Abstract
Is tamoxifen the Rosetta stone for breast cancer?: V.C. Jordan; J. Natl. Cancer Inst. 95, 338 (2003) Abstract
 
 

Your items will be kept only for the duration of your visit.